Contact Us Facebook

Bladder Cancer

Bladder cancer begins when abnormal cells in the bladder grow and divide in an uncontrolled way. Because every patient’s situation is unique, our team at Illinois CancerCare focuses on early detection, accurate diagnosis, and personalized treatment plans designed to give you the best possible outcome. Most bladder cancers start in the urothelial (transitional) cells that line the inside of the bladder and urinary tract.

Understanding the Bladder

The bladder is a hollow, muscular organ in the lower abdomen that stores urine before it leaves the body. Urine is produced by the kidneys, travels through the ureters into the bladder, and exits via the urethra. The bladder’s inner lining is made of urothelial cells that can stretch as the bladder fills and shrink as it empties—this unique lining is also where most bladder cancers begin.

Types of Bladder Cancer

Urothelial (transitional cell) carcinoma

The most common type in the U.S. It starts in the urothelial lining and can occur anywhere along the urinary tract (renal pelvis, ureter, bladder, proximal urethra).

Squamous cell carcinoma

Less common in the U.S.; often linked to chronic irritation or infection (including schistosomiasis in some regions).

Adenocarcinoma

Rare; arises from gland‑forming cells in the bladder lining.

Small cell (neuroendocrine) carcinoma

Very rare, typically aggressive, and treated with multimodal therapy.

Your care team will explain your tumor’s cell type and whether it is non‑muscle‑invasive or muscle‑invasive, as this is a key driver of treatment decisions.

Signs & Symptoms

  • Blood in the urine (hematuria)—often painless and intermittent
  • Urinary urgency or frequency
  • Pain or burning with urination
  • Pelvic, lower back, or flank pain (more common with advanced disease) Many non‑cancer conditions can cause similar symptoms. If you notice persistent or recurrent urinary symptoms—especially visible blood in the urine—talk with your doctor.

Risk Factors

  • Tobacco use (the leading risk factor)
  • Occupational exposures to certain chemicals (e.g., in dyes, rubber, leather, metal, printing)
  • Age (risk increases over 55) and male sex
  • Chronic bladder irritation (e.g., long‑term catheters, certain infections)
  • Prior pelvic radiation or certain chemotherapy drugs
  • Arsenic‑contaminated water (varies by region)
  • Family history and certain inherited conditions

Having one or more risk factors doesn’t mean you will develop bladder cancer, and many people diagnosed have no identifiable risks.

Screening

There is no standard screening test proven to reduce deaths among people at average risk. For those with prior bladder cancer or in select higher‑risk groups, clinicians may recommend periodic cystoscopy, urine cytology, or urine‑based markers as part of surveillance or evaluation for symptoms.

Diagnosis

Your diagnosis and treatment plan are informed by several steps:

Treating lung disease, heart problems, sleep apnea, or kidney issues can help correct secondary erythrocytosis.

For certain types—especially polycythemia—periodic removal of blood may help lower red blood cell levels and reduce symptoms or clot risk.

Some patients may need medicines to reduce red blood cell production or treat complications. Your provider will discuss these options if needed.

  • Stay well‑hydrated
  • Avoid smoking
  • Manage sleep apnea if present
  • Report new symptoms promptly

Your team will tailor testing to your situation and explain results and next steps.

Staging & Categories

Bladder cancer is commonly grouped as:

Non‑muscle‑invasive (NMIBC)

Confined to the inner layers (Ta/T1) or carcinoma in situ (Tis).

Muscle‑invasive (MIBC)

Has grown into the muscle layer of the bladder wall (T2+) and may extend into nearby tissues or lymph nodes.

Metastatic

Has spread to distant lymph nodes or other organs.
Formal staging (0–IV) combines tumor depth (T), lymph nodes (N), and metastasis (M), but the NMIBC vs MIBC distinction often guides initial treatment planning.

Treatment Options

Treatment is individualized based on stage, tumor grade, pathology, molecular findings, overall health, and your goals. Care is coordinated by a multidisciplinary team.

For Non‑Muscle‑Invasive Bladder Cancer (NMIBC)

  • TURBT to remove visible tumors
  • Intravesical therapy placed directly into the bladder
  • BCG immunotherapy (standard for many high‑risk NMIBC cases)
  • Intravesical chemotherapy (e.g., immediate post‑TURBT gemcitabine or mitomycin; induction/maintenance for intermediate‑ or high‑risk disease)
  • Risk‑adapted surveillance with periodic cystoscopy and urine testing

For Muscle‑Invasive Bladder Cancer (MIBC)

  • Radical cystectomy (bladder removal) with urinary diversion, commonly paired with neoadjuvant chemotherapy
  • Bladder‑preserving approaches in select patients (maximal TURBT + concurrent chemoradiation)

For Advanced / Metastatic Disease

  • Systemic therapy (platinum‑based chemotherapy, immunotherapy with checkpoint inhibitors)
  • Targeted/novel agents (e.g., antibody‑drug conjugates) based on prior therapies and eligibility
  • Palliative radiation or procedures to relieve symptoms when appropriate

Your Illinois CancerCare team will discuss benefits and potential side effects and whether a clinical trial may be right for you.

Prognosis

Many bladder cancers—especially non‑muscle‑invasive disease—are highly treatable, though careful surveillance is essential because recurrence is common. Overall outcomes depend on stage, grade, response to therapy, pathology, and overall health. National statistics provide context (for example, approximate 5‑year relative survival for all stages combined is around 79%), but your doctor will explain what your individual features mean.

Follow Up Care

Follow‑up typically includes regular cystoscopy, urine cytology or markers, and periodic imaging based on your risk category and treatment. The schedule is more frequent in the first years after treatment and is tailored to your diagnosis.

Living With Bladder Cancer

Illinois CancerCare offers comprehensive support, including counseling, nutrition guidance, rehabilitation, survivorship programs, caregiver resources, and access to clinical trials—all designed to help you and your loved ones navigate treatment and recovery. National organizations (e.g., ACS) provide additional education and tools for patients and caregivers.

Why Choose Illinois CancerCare

  • Experienced multidisciplinary team in medical oncology and radiation oncology, with urology partners for surgical care
  • Advanced diagnostics and timely, coordinated treatment planning
  • Compassionate, patient‑centered care close to home
  • Access to innovative treatments and clinical trials through our active research program (See our Current Clinical Trials page for bladder/urinary tract studies that may be available to you.)

Sources & Patient Friendly References

All information was taken from the NCI (National Cancer Institute) and ACS (American Cancer Society).